HENGRUI PHARMA (01276.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec19

Hengrui Pharmaceutical's Subsidiary Obtains Clinical Trial Approval for Leuprorelin Acetate Microspheres Injection

12:01

Hengrui Medicine Subsidiary Receives Clinical Trial Approval Notice for SHR-2906 Injection

08:57

Dec16

Zhang Jialin: China's Pharmaceutical Industry to Accelerate AI Applications with Four Major Risks Next Year

08:37

Dec15

Hengrui Medicine Receives Clinical Trial Approvals for Four Products

00:22

Dec12

Hengrui Medicine's Subsidiary Receives Clinical Trial Approval Notice for RSS0343 Tablets from NMPA

11:57

HRS9531 Injection Approved for Clinical Trials by Huahai Medicine's Subsidiary

11:53

Schedules & Filings

Schedules

Filings

Oct27

Earning Release(CST)

FY2025 Q3 Earning Release (HKD) Revenue 8.119 B, Net Income 1.422 B, EPS 0.2131

Aug20

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 9.364 B, Net Income 2.82 B, EPS 0.4359

May23

IPO(CST)

Listing Price HKD 44.05

View More

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change

View More